查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631159

神经内分泌肿瘤治疗市场规模、份额、趋势分析报告：按类型、产品、地点、最终用途、地区和细分市场进行预测，2025 年至 2030 年

Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Type (Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma), By Product, By Site, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

神经内分泌肿瘤治疗市场的成长与趋势

根据Grand View Research, Inc.的新报告，到2030年全球神经内分泌肿瘤治疗市场规模预计将达37.3亿美元。

预计 2025 年至 2030 年间，该市场的复合年增长率将达到 6.0%。预计在预测期内，类癌瘤盛行率的增加将推动市场的发展。推动市场发展的另一个因素是各製药公司在临床试验方面投入大量资金来开发新产品。

例如，诺华公司拥有最多的临床试验，其次是辉瑞公司和益普生製药公司。此外，治疗神经内分泌肿瘤的治疗方法技术进步预计将在未来几年推动市场成长。这些包括采用 Ga标记的生长抑制素的 PET 影像、标靶药物治疗和蛋白酪氨酸激酶治疗。例如，诺华公司的Lutathera是第一个获得FDA核准的放射性核苷酸疗法。

神经内分泌肿瘤治疗市场报告重点

  • 随着类癌瘤盛行率不断上升以及治疗技术不断进步，类癌瘤领域将占据市场主导地位，2024 年的收入份额为 24.3%。
  • 生长抑制素类似物 (SSA) 部门在 2024 年的收入份额方面占据了市场主导地位，因为它们已被证明可有效控制与神经内分泌肿瘤相关的症状。
  • 小肠部分占据市场主导地位，占据 2024 年最大的收益占有率。
  • 2024 年，医院部门占据市场主导地位，收益占有率最大，这得益于医院为复杂的神经内分泌肿瘤病例提供的全面护理。
  • 北美神经内分泌肿瘤治疗市场占据全球市场主导地位，2024年的收益占有率为42.1%。

目录

第一章调查方法与范围

第 2 章执行摘要

3. 神经内分泌肿瘤治疗市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析 – 波特五力分析
    • PESTLE分析

第 4 章神经内分泌肿瘤治疗市场：按类型分類的商业分析

  • 2024 年及 2030 年类型市场占有率
  • 类型细分仪表板
  • 2018 年至 2030 年按类型分類的市场规模、预测与趋势分析
  • 脑膜瘤
  • 肾上腺癌
  • 类癌肿瘤
  • 副神经节瘤
  • 嗜铬细胞瘤
  • 其他的

第五章神经内分泌肿瘤治疗市场：产品业务分析

  • 2024 年及 2030 年产品市场占有率
  • 产品细分仪表板
  • 2018 年至 2030 年按产品分類的市场规模、预测与趋势分析
  • 生长抑制素类似物 (SSA)
  • 标靶治疗
  • 其他的

第 6 章神经内分泌肿瘤治疗市场：基于站点的商业分析

  • 2024 年及 2030 年零件市场占有率
  • 身体部位细分仪表板
  • 2018 年至 2030 年按身体部位分類的市场规模、预测与趋势分析
  • 肺
  • 胰臟
  • 冒号
  • 小肠
  • 直肠
  • 胃
  • 其他的

7. 神经内分泌肿瘤治疗市场-最终用途业务分析

  • 2024 年及 2030 年终端用途市场占有率
  • 最终用途细分仪表板
  • 2018 年至 2030 年按最终用途分類的市场规模、预测和趋势分析
  • 医院
  • 诊所
  • 其他的

第 8 章神经内分泌肿瘤治疗市场：按地区分類的估计和趋势

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030 年市场规模及预测趋势分析
  • 北美洲
    • 按国家/地区，2018 年至 2030 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区，2018 年至 2030 年
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 新加坡
  • 拉丁美洲
    • 按国家/地区，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 按国家/地区，2018 年至 2030 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Boehringer Ingelheim International GmbH
    • Hutchison MediPharma Limited.
    • AVEO Pharmaceuticals, Inc.
    • Ipsen Pharma.
    • Eli Lilly and Company.
    • Exelixis, Inc.
    • Jubilant Pharmova Limited
Product Code: GVR-2-68038-624-0

Neuroendocrine Tumor Treatment Market Growth & Trends:

The global neuroendocrine tumor treatment market size is expected to reach USD 3.73 billion by 2030, according to a new report by Grand View Research, Inc. The market is estimated to register a CAGR of 6.0% from 2025 to 2030. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

Neuroendocrine Tumor Treatment Market Report Highlights:

  • The carcinoid tumors segment dominated the market with a revenue share of 24.3% in 2024, driven by the increasing prevalence of carcinoid tumors and advancements in treatment methodologies.
  • The Somatostatin Analogs (SSAs) segment dominated the market with the largest revenue share in 2024, attributed to their proven efficacy in managing symptoms associated with neuroendocrine tumors.
  • The small intestine segment dominated the market with the largest revenue share in 2024, attributed to the higher incidence rates of neuroendocrine tumors originating from this site.
  • The hospitals segment dominated the market with the largest revenue share in 2024, driven by the comprehensive care offered by hospitals for complex cases of neuroendocrine tumors.
  • North America neuroendocrine tumor treatment market dominated the global market with a revenue share of 42.1% in 2024, driven by high healthcare expenditure coupled with advanced medical infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Site
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Neuroendocrine Tumor Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Neuroendocrine Tumor Treatment Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 4.4. Meningiomas
    • 4.4.1. Meningiomas Market, 2018 - 2030 (USD Billion)
  • 4.5. Adrenal Cancer
    • 4.5.1. Adrenal Cancer Market, 2018 - 2030 (USD Billion)
  • 4.6. Carcinoid Tumors
    • 4.6.1. Carcinoid Tumors Market, 2018 - 2030 (USD Billion)
  • 4.7. Paraganglioma
    • 4.7.1. Paraganglioma Market, 2018 - 2030 (USD Billion)
  • 4.8. Pheochromocytoma
    • 4.8.1. Pheochromocytoma Market, 2018 - 2030 (USD Billion)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 5. Neuroendocrine Tumor Treatment Market: Product Business Analysis

  • 5.1. Product Market Share, 2024 & 2030
  • 5.2. Product Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 5.4. Somatostatin Analogs (SSAs)
    • 5.4.1. Somatostatin Analogs (SSAs)Market, 2018 - 2030 (USD Billion)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Neuroendocrine Tumor Treatment Market: Site Business Analysis

  • 6.1. Site Market Share, 2024 & 2030
  • 6.2. Site Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Site, 2018 to 2030 (USD Billion)
  • 6.4. Lung
    • 6.4.1. Lung Market, 2018 - 2030 (USD Billion)
  • 6.5. Pancreas
    • 6.5.1. Pancreas Market, 2018 - 2030 (USD Billion)
  • 6.6. Colon
    • 6.6.1. Colon Market, 2018 - 2030 (USD Billion)
  • 6.7. Small Intestine
    • 6.7.1. Small Intestine Market, 2018 - 2030 (USD Billion)
  • 6.8. Rectum
    • 6.8.1. Rectum Market, 2018 - 2030 (USD Billion)
  • 6.9. Stomach
    • 6.9.1. Stomach Market, 2018 - 2030 (USD Billion)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Neuroendocrine Tumor Treatment Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 7.4. Hospitals
    • 7.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 7.5. Clinics
    • 7.5.1. Clinics Market, 2018 - 2030 (USD Billion)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Neuroendocrine Tumor Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.7. Singapore
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Singapore Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8. MEA
    • 8.8.1. MEA Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Type Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Bristol-Myers Squibb Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Type Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Pfizer Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Type Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Boehringer Ingelheim International GmbH
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Type Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Hutchison MediPharma Limited.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Type Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AVEO Pharmaceuticals, Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Type Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Ipsen Pharma.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Type Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Eli Lilly and Company.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Type Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Exelixis, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Type Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Jubilant Pharmova Limited
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Type Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global neuroendocrine tumor treatment market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 5 Global neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 6 Global neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 7 Global neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 8 North America neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 9 North America neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 10 North America neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 11 North America neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 12 North America neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 13 U.S. neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 14 U.S. neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 15 U.S. neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 16 U.S. neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 17 Canada neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 18 Canada neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 19 Canada neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 20 Canada neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 21 Mexico neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 22 Mexico neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 23 Mexico neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 24 Mexico neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 25 Europe neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 26 Europe neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 27 Europe neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 28 Europe neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 29 Europe neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 30 UK neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 31 UK neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 32 UK neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 33 UK neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 34 Germany neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Germany neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 36 Germany neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 37 Germany neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 38 France neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 39 France neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 40 France neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 41 France neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 Italy neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 43 Italy neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 44 Italy neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 45 Italy neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 46 Spain neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 47 Spain neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 48 Spain neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 49 Spain neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 50 Norway neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 51 Norway neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 52 Norway neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 53 Norway neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 54 Denmark neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 55 Denmark neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 56 Denmark neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 57 Denmark neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 58 Sweden neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 59 Sweden neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 60 Sweden neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 61 Sweden neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 62 Asia Pacific neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 63 Asia Pacific neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 64 Asia Pacific neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 65 Asia Pacific neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 66 Asia Pacific neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 67 Japan neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 68 Japan neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 69 Japan neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 70 Japan neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 71 China neuroendocrine tumor treatment market, by type, 2018-2030 (USD Billion)
  • Table 72 China neuroendocrine tumor treatment market, by product, 2018-2030 (USD Billion)
  • Table 73 China neuroendocrine tumor treatment market, by site, 2018-2030 (USD Billion)
  • Table 74 China neuroendocrine tumor treatment market, by end use, 2018-2030 (USD Billion)
  • Table 75 India neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 76 India neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 77 India neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 78 India neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 79 Australia neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 80 Australia neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 81 Australia neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 82 Australia neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 83 South Korea neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 84 South Korea neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 85 South Korea neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 86 South Korea neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 87 Singapore neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 88 Singapore neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 89 Singapore neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 90 Singapore neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 91 Latin America neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 92 Latin America neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 93 Latin America neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion
  • Table 94 Latin America neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion
  • Table 95 Latin America neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion
  • Table 96 Brazil neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 97 Brazil neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 98 Brazil neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 99 Brazil neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 100 Argentina neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 101 Argentina neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 102 Argentina neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 103 Argentina neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 104 Middle East & Africa neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 105 Middle East & Africa neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 106 Middle East & Africa neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 107 Middle East & Africa neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 108 Middle East & Africa neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 109 South Africa neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 110 South Africa neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 111 South Africa neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 112 South Africa neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 116 Saudi Arabia neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 117 UAE neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 118 UAE neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 119 UAE neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 120 UAE neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 121 Kuwait neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 124 Kuwait neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Neuroendocrine tumor treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type outlook (USD Billion)
  • Fig. 10 Product outlook (USD Billion)
  • Fig. 11 Site outlook (USD Billion)
  • Fig. 12 End Use outlook (USD Billion)
  • Fig. 13 Competitive landscape
  • Fig. 14 Neuroendocrine tumor treatment market dynamics
  • Fig. 15 Neuroendocrine tumor treatment market: Porter's five forces analysis
  • Fig. 16 Neuroendocrine tumor treatment market: PESTLE analysis
  • Fig. 17 Neuroendocrine tumor treatment market: Type segment dashboard
  • Fig. 18 Neuroendocrine tumor treatment market: Type market share analysis, 2024 & 2030
  • Fig. 19 Meningiomas market, 2018 - 2030 (USD Billion)
  • Fig. 20 Adrenal Cancer market, 2018 - 2030 (USD Billion)
  • Fig. 21 Carcinoid Tumors market, 2018 - 2030 (USD Billion)
  • Fig. 22 Paraganglioma market, 2018 - 2030 (USD Billion)
  • Fig. 23 Pheochromocytoma market, 2018 - 2030 (USD Billion)
  • Fig. 24 Others market, 2018 - 2030 (USD Billion)
  • Fig. 25 Neuroendocrine tumor treatment market: Product segment dashboard
  • Fig. 26 Neuroendocrine tumor treatment market: Product market share analysis, 2024 & 2030
  • Fig. 27 Somatostatin analogs (SSAs) market, 2018 - 2030 (USD Billion)
  • Fig. 28 Targeted therapy market, 2018 - 2030 (USD Billion)
  • Fig. 29 Others market, 2018 - 2030 (USD Billion)
  • Fig. 30 Neuroendocrine tumor treatment market: Site segment dashboard
  • Fig. 31 Neuroendocrine tumor treatment market: Site market share analysis, 2024 & 2030
  • Fig. 32 Lung market, 2018 - 2030 (USD Billion)
  • Fig. 33 Pancreas market, 2018 - 2030 (USD Billion)
  • Fig. 34 Colon market, 2018 - 2030 (USD Billion)
  • Fig. 35 Small Intestine market, 2018 - 2030 (USD Billion)
  • Fig. 36 Rectum market, 2018 - 2030 (USD Billion)
  • Fig. 37 Stomach market, 2018 - 2030 (USD Billion)
  • Fig. 38 Others market, 2018 - 2030 (USD Billion)
  • Fig. 39 Neuroendocrine tumor treatment market revenue, by region
  • Fig. 40 Regional marketplace: Key takeaways
  • Fig. 41 North America neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 42 U.S. country dynamics
  • Fig. 43 U.S. neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 44 Canada country dynamics
  • Fig. 45 Canada neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 46 Mexico country dynamics
  • Fig. 47 Mexico neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 48 Europe neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 49 UK country dynamics
  • Fig. 50 UK neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 51 Germany country dynamics
  • Fig. 52 Germany neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 53 France country dynamics
  • Fig. 54 France neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 55 Italy country dynamics
  • Fig. 56 Italy neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 57 Spain country dynamics
  • Fig. 58 Spain neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 59 Norway country dynamics
  • Fig. 60 Norway neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 61 Denmark country dynamics
  • Fig. 62 Denmark neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion
  • Fig. 63 Sweden country dynamics
  • Fig. 64 Sweden neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 65 Asia Pacific neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 66 Japan country dynamics
  • Fig. 67 Japan neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 68 China country dynamics
  • Fig. 69 China neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 70 India country dynamics
  • Fig. 71 India neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 72 South Korea country dynamics
  • Fig. 73 South Korea neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 74 Australia country dynamics
  • Fig. 75 Australia neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 76 Singapore country dynamics
  • Fig. 77 Singapore neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 78 Latin America neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 79 Brazil country dynamics
  • Fig. 80 Brazil neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 81 Argentina country dynamics
  • Fig. 82 Argentina neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 83 MEA neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 84 South Africa country dynamics
  • Fig. 85 South Africa neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 86 Saudi Arabia country dynamics
  • Fig. 87 Saudi Arabia neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 88 UAE country dynamics
  • Fig. 89 UAE neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 90 Kuwait country dynamics
  • Fig. 91 Kuwait neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 92 Company categorization
  • Fig. 93 Company market position analysis
  • Fig. 94 Strategic framework